$IDXG

INTERPACE BIOSCIENCES, INC.

Interpace Biosciences provides molecular diagnostic testing and pathology services to help physicians assess cancer risk and guide patient diagnosis and management. Its clinical services business focuses on tests for indeterminate thyroid nodules, with hospitals, physicians, cancer centers, clinics, commercial laboratories and pathology groups among its customers. Its commercialized tests are ThyGeNEXT®, a DNA and RNA sequencing panel that analyzes mutations and gene fusions, and ThyraMIR®v2, a microRNA-based classifier used with ThyGeNEXT® to refine malignancy risk. The company discontinued PancraGEN® sales in May 2025. Interpace Biosciences performs testing in its CLIA-certified and CAP-accredited laboratory in Pittsburgh, Pennsylvania. It earns money through reimbursement from Medicare, Medicare Advantage, Medicaid and commercial payers, as well as direct client billings. Its sales and marketing efforts use direct and indirect channels and focus predominantly on the United States.

0
1
0

No SEC Form 4 filings for $IDXG in the last 30 days.

See all $IDXG insider activity →

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue ● Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million ● Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 ● Expected ye

IDXG sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning IDXG (INTERPACE BIOSCIENCES, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent IDXG coverage spans earnings and corporate actions.

What's driving IDXG

AlphAI scores every news story that mentions IDXG with an AI model for sentiment and relevance, and aggregates insider trades from INTERPACE BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IDXG

Score
$IDXGMedEarnings

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue ● Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million ● Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 ● Expected ye

$IDXGMedShareholder vote

INTERPACE BIOSCIENCES, INC. (IDXG): Submission of Matters to a Vote of Security Holders

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 20, 2026, the Company held its 2026 annual meeting of stockholders (the “ 2026 Annual Meeting ”). The following proposals were voted on and approved by the Company’s stockholders at the 2026 Annual Meeting

$IDXGMedEarnings

Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results ● Q2 Revenue of $9.1 million ● Q2 Income from Continuing Operations of $0.3 million ● Q2 Thyroid volume year-over-year increase of 6% ● Q2 Thyroid revenue year-over-year increase of 9%

Related tickers